Close Menu

NEW YORK (GenomeWeb) – Thermo Fisher Scientific has signed agreements with Daiichi Sankyo and Takeda Pharmaceuticals to use its Oncomine Dx Target Test in clinical trials and drug development programs.

Under the terms of those partnerships, Thermo will validate additional biomarkers and gene variants on Oncomine and retain global commercialization rights for the test. The company will also be responsible for filing supplemental premarket approval applications with the US Food and Drug Administration.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.